Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$7.35 USD
-0.10 (-1.34%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $7.33 -0.02 (-0.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADVM 7.35 -0.10(-1.34%)
Will ADVM be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ADVM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADVM
Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?
ADVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
Other News for ADVM
Strong Buy Rating for Adverum Biotechnologies Amid Anticipated Positive Phase 2 Results and Market Undervaluation
Adverum Biotechnologies (ADVM) Receives a Buy from Truist Financial
Buy Rating Affirmed for Adverum’s Gene Therapy on Promising Interim Phase 2 Results and Potential Standard of Care Shift in nAMD Treatment
Adverum Biotechnologies (ADVM) Receives a New Rating from RBC Capital
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress